After the discovery of activating mutations in EGFR, EGFR tyrosine kinase inhibitors (TKIs)
have been introduced into the first-line treatment of non-small-cell lung cancer (NSCLC). A …

High-quality genomic analysis is critical for personalized pharmacotherapy in patients with
cancer. Tumor-specific genomic alterations can be identified in cell-free DNA (cfDNA) from …

Background In a significant percentage of advanced non-small-cell lung cancer (NSCLC)
patients, tumor tissue is unavailable or insufficient for genetic analyses. We prospectively …

An accurate blood‐based RAS mutation assay to determine eligibility of metastatic
colorectal cancer (mCRC) patients for anti‐EGFR therapy would benefit clinical practice by …

Despite advances in the management of non-small cell lung cancer, it remains to be the
leading cause of cancer-related deaths worldwide primarily because of diagnosis at a late …

Abstract EGFR (exon 19 and exon 21) mutations in patients with advanced non-small cell
lung cancer (NSCLC) treated by EGFR-TKIs are associated with a better survival; while …

Liquid biopsy is a blood test that detects evidence of cancer cells or tumor DNA in the
circulation. Despite complicated collection methods and the requirement for technique …

Lung cancer care is rapidly changing with advances in genomic testing, the development of
next-generation targeted kinase inhibitors, and the continued broad study of immunotherapy …

Molecular profiling and the discovery of drugs that target specific activating mutations have
allowed the personalization of treatment for non‐small cell lung cancer (NSCLC). The …

Circulating tumor DNA (ctDNA) consists of short double stranded DNA fragments that are
released by tumors including non-small cell lung cancer (NSCLC). With the identification of …